Avanzanite Bioscience

Privately held: no public share price · Netherlands

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Mitapivat(Pyrukynd)
Approved
Pyruvate kinaseSmall molecule
Sickle Cell DiseasePyruvate Kinase DeficiencyBeta-Thalassemia
Transfusion-Dependent Beta Thalassemia

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (3)
March 2029 (1)
Mitapivat · PyrukyndPhase 3Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Est. primary completion 2029-03 · NCT07517133 · CT.gov ↗
What to watch
June 2029 (1)
Mitapivat · PyrukyndPhase 3Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia
Est. primary completion 2029-06 · NCT07506863 · CT.gov ↗
What to watch
August 2029 (1)
Mitapivat · PyrukyndPhase 3Sickle Cell Disease
Est. primary completion 2029-08 · NCT07656415 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

1 February 2027FDA action dateMitapivatMitapivat sickle cell sNDA PDUFA goal date extended to 1 February 2027
US, FDA · Source ↗

Recent

12 May 2026Filing submittedMitapivatAgios submits mitapivat sNDA for sickle cell disease
US, FDA · AGIOS PHARMACEUTICALS, INC. · Source ↗
November 2025Topline resultMitapivatRISE UP Phase 3 of mitapivat in sickle cell disease (NCT05031780): hemoglobin response met; pain crisis rate not significant
Agios Pharmaceuticals, Inc. · Source ↗

Financial reports

No financial reports recorded.